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Abstract
Introduction: There is an ongoing debate regarding the need to conduct intraoperative 
defibrillation testing (DFT) at the time of implantable cardioverter-defibrillator (ICD) 
implantation. To provide sufficiently strong evidence for the feasibility of omitting 
intraoperative DFT in clinical practice, we conducted a meta-analysis of randomized 
controlled trials (RCT) comparing patients with DFT and no-DFT.
Methods: We systematically searched Medline (via PubMed), ClinicalTrial.gov, the 
Cochrane Central Register of Controlled Trials, and Embase for studies evaluating DFT 
vs. no-DFT on ICD implantation with regard to total mortality and arrhythmic death, 
efficacy of first and any appropriate shock in interrupting ventricular tachycardia (VT)/
ventricular fibrillation (VF), and procedural adverse events. Effect estimates [risk ratio 
(RR) with 95% confidence intervals (CI)] were pooled using the random-effects model.
Results: Our meta-analysis included 4 RCTs comprising 3770 patients (1896 with 
DFT and 1874 without DFT). Total mortality (RR = 1.00, 95% CI 0.86–1.17; P = 0.98) 
and arrhythmic death (RR = 1.60, 95% CI 0.46-5.59: P = 0.46) were not statistically 
different. Both first (RR = 0.94, 95% CI 0.89–0.98; P = 0.004) and any appropriate 
ICD shock (RR = 0.97, 95% CI 0.95–1.00; P = 0.02) significantly increased the rate of 
VT/VF interruption in the group with no-DFT in comparison with DFT. Finally, the 
incidence of adverse events was lower in no-DFT patients (RR = 1.23; 95% CI 1.00–
1.51; P = 0.05).
Conclusions: The practice of DFT (as opposed to no-DFT) did not yield benefits 
in mortality or the overall rate of conversion of VT/VT. Moreover, a slightly higher 
incidence of perioperative adverse events was observed in the DFT group.
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Testing of the implantable cardioverter-defibrillator (ICD) 
for its ability to correctly sense, detect and terminate ventric-
ular fibrillation (VF) has been an important part of device 
implantation since procedures in humans began in the early 
1980s. In recent years, the advent of the biphasic waveform, 
better understanding of optimal shock waveform/duration, 
and higher-shock energy devices, have led some to question 
the need for defibrillation testing (DFT) [1]. Furthermore, 
controversy over whether to perform DFT has focused on 
possible adverse clinical events [1-4]. A prior systematic re-
view by Phan et al. [5] demonstrates no significant benefit for 
DFT in terms of mortality, ICD efficacy or 30-day post-im-
plant complications. In this systematic review and meta-anal-
ysis, we sought to update the effect of DFT on the risks of 
all-cause mortality, arrhythmic death, appropriate shock effi-
cacy, and procedural adverse events.
METHODS
This analysis was performed in adherence to the Preferred 
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Reporting Items for Systemic reviews and Meta-Analyses 
(PRISMA) statement on the quality of reporting of me-
ta-analyses [6]ZiғK’p.
Search Strategy
We searched the Medline (via PubMed), ClinicalTrials.gov, 
and the Cochrane Central Register of Controlled Trials 
for studies of DFT testing in ICD that had been published 
through June 31, 2017. Medical Subject Headings (MeSH) 
and keywords included the following: (1) implantable car-
dioverter-defibrillators, (2) DF test, (3) intra-operative DF 
testing, (4) ventricular tachycardia, and (5) ventricular fibril-
lation. In addition, we searched for meeting abstracts in Em-
base and hand-searched references and related citations in 
review articles and commentaries.
Study Selection and Eligibility Criteria
The primary outcome was all-cause mortality. Secondary 
outcomes included arrhythmic death and appropriate shock 
efficacy. Data on safety included procedural adverse events 
and complications as defined by the individual studies in-
cluded. Only randomized studies that followed patients for 
≥6 months and in which mortality data were reported or 
available from the authors were included.
Quality Assessment
The internal validity of included studies was assessed using 
the Cochrane Collaboration’s tool for assessing risk of bias in 
randomized trials [7].
Data Synthesis and Statistical Analysis
Data were pooled and analyzed by means of Review Manager 
(RevMan) [Computer program]. Version 5.3. Copenhagen: 
The Nordic Cochrane Centre, The Cochrane Collaboration, 
2014. The random-effects model was used for the analyses. 
The effect size is presented as relative risk (RR). Statistical 
heterogeneity was evaluated using the I2 statistic and its 95% 
confidence interval (CI) [8]. A sensitivity analysis was per-
formed by estimating the pooled effect sizes after leaving 




Our literature search identified 484 publications (Fig 1). Six-
teen articles were assessed for eligibility. Four RCTs met the 
inclusion criteria [Shockless IMPLant Evaluation (SIMPLE) 
[3], NO Regular Defibrillation testing In Cardioverter De-
fibrillator Implantation (NORDIC ICD) [9], Resynchroni-
zation for Ambulatory Heart Failure substudy (RAFT DFT) 
[10], and Test-No Test Implantable Cardioverter Defibrilla-
tor Pilot Study (TNT ICD) [11]]. These 4 studies included 
3770 (1896 DFT and 1874 no-DFT) participants. Table 1 
summarizes the characteristics and Fig 2 reported the quality 
assessment of the studies included.
Table 1: Characteristics of the Included Studies
RAFT DFT NORDIC ICD SIMPLE TNT ICD
ClinicalTrials.gov Identifier
NCT00251251 NCT01282918 NCT00800384 NCT01905007
Study design
Randomized 1:1 Randomized 1:1 Randomized 1:1 Randomized 1:1
Paralell (2-arm) Parallel (2-arm) Parallel (2-arm) Paralell (2-arm)
Open-label Open-label Single-blind Open-label
Pilot Non-inferiority Non-inferiority Pilot
Centers
Multicenter, 34 sites Multicenter, 48 sites Multicenter, 85 sites Multicenter, 2 sites
Participants
145 1077 2500 48
Inclusion criteria
 RAFT inclusion criteria (NYHA Class
 II, LVEF ≤ 30%; intrinsic QRS complex
width ≥ 120 ms or paced QRS measure-
ment ≥ 200 ms, ICD indication for pri-
 mary or secondary prevention, optimal
 heart failure pharmacological therapy,
 normal sinus rhythm or chronic
 persistent atrial tachyarrhythmia with
 resting ventricular heart rate ≤ 60 bpm
 and 6 minute hall walk ventricular heart
 rate of ≤ 90 bpm; or chronic persistent
 atrial tachyarrhythmia with resting
 ventricular heart rate > 60 bpm and 6
 minute hall walk ventricular heart rate >
 90 bpm and booked for atrioventricular
junction ablation)
 Age ≥ 18 years, initial ICD
 implantation or CRT-D for Class
 I indication according to the
ACC/AHA/ESC 2006 guideli-
 nes and the 2010 focused update
 of ESC guidelines on device
therapy in heart failure
 Age ≥ 18 years, inizial implantation
of ICD or CRT-D
 Age ≥ 18 years,
initial ICD implan-
 tation or CRT-D for
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Exclusion criteria
 Documented intracardiac thrombus,
 persistent/permanent AF without
 appropriate anticoagulation, right-site
 implant, inelegible for either DFT
 strategy PLUS RAFT exlusion criteria
 (intravenous inotropic agent in the last
 4 days, life expectancy ≤ 1 year from
 non-cardiac cause, expected to undergo
 cardiac transplantation within 1 year,
 acute cardiac or non-cardiac illness that
 requires intensive care, uncorrected or
 uncorrectable primary valvular disease,
 restrictive, hypertrophic, or reversible
form of cardiomyopathy, severe prima-
 ry pulmonary hypertension, tricuspid
 prosthetic valve, existing ICD, coronary
 revascularization < 1 month and
 LVEF > 30%, ACS with LVEF > 30%,
 included in another clinical trial that
 will affect the objectives of this study,
 history of noncompliance to medical
therapy)
ARVC or hypertrophic cardiomy-
 opathy, VF due to acute ischemia
 or other potentially reversible
causes, actively listed for a trans-
plant, unable or unwilling to par-
 ticipate in the study, unavailable
 for required follow-ups and study
procedures, participating in an-
 other clinical study other than a
registry or observational/non-in-
 terventional study, anticipated
 right sided implantation of ICD
 generator, malignant condition
 with a life expectancy less than
the duration of the study, preg-
 nant and breast-feeding women,
terminal renal insufficiency, per-
 sistent AF without pre-operative
 TEE, persistent AF with left atrial
thrombus diagnosed by TEE
 Ineligible for either DFT strategy,
on active transplant list, unavail-
 able for follow-up, pregnancy or
 women of child bearing potential
 not following an effective method
 of contraception, anticipated right
sided implantation
 Contraindications
to DFT as de-








 (for > 6 weeks and
 continued need for
amiodarone), inabil-
 ity to give informed
consent
Device & Sponsor
Medtronic Biotronik Boston Scientific Medtronic
Follow-up
24.2 months (mean) 37 months (mean) 14.9 months (mean)
Primary endpoint
 SAFETY. Composite of death, stroke,
 systemic embolism, myocardial
 infarction, heart failure (requiring
 intravenous diuretics, inotropes or
rehospitalization), hypotension (requir-
 ing intravenous vaso- constrictors or
 inotropes for > 15 minutes), need for
chest compressions or intraaortic bal-
 loon pump, non-elective intubation or
aspiration, unplanned ICU stay, pneu-
 mothorax, pericardial tamponade or
 pericarditis, device infection (requiring
 removal or IV antibiotics), arterial-line
 complication (requiring intervention)
(within 30 days). EFFICACY. Com-
 posite of failed appropriate ICD shock
or arrhythmic death
 Average efficacy of the first ICD
 shock for all true ventricular
tachyarrhythmias
 Composite of failed approriate






 All-cause mortality or hospitalization
 for heart failure, all-cause mortality and
length of hospital stay
 SAFETY. Serious adverse events
(within 30 days), blood parame-
 ters indicating myocardial injury
 [BNP, Creatinine, Troponin T,
 CK, CK-MB], system revisions
 at implant, total fluoroscopy and
 implantation time. EFFICACY.
 All-cause mortality, cardiac
 mortality, arrhythmic mortality,
 ventricular tachyarrhythmia
 conversion efficacy of the ICD
shock therapy
 Composite of death, stroke,
 non-CNS systemic embolism,
 pulmonary embolism, myocardial
 infarction, heart failure (needing
inotropes or diuretics), intraop-
 erative hypotension, need for
 chest compression, non-elective
 intubation, aspiration pneumonia,
 unplanned ICU stay, pneumotorax,
pericarditis, cardiac perforation, par-
 diac tamponade, device infection,
 arterial-line complication, anoxic
brain injury (within 30 days)




1/1 success at 15 J 1/1 success at 15 J 1/1 success at 17 J N/A
1/1 success at 25 J 2/2 success at 24 J 2/2 success at 21 J N/A
Programmed arrhythmia detection and therapies
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 VF-250 bpm; NID 18 of 24; first VF
 therapy 25J; maximum energy ( J not
specified) x 5
 VF-222 bpm; NID 12 of 16; ATP
one shot (if history of mono-
 morphic VT in the zone of VF);
40 J x 8
 VF-230 bpm/250 bpm; 1 s delay;
 first VF therapy 31 J; second-last VF
terapy 31/41 J
N/A
 FVT-200 bpm; NID 18 of 24; ATP x 1;
 second FVT therapy 25 J; maximum
energy ( J not specified) x 4
 VT-188 bpm; NID 26; ATP at
discretion; 40 J x 8
 VT-180 bpm; 2,5 s delay; first VT
 therapy: ATP x 6 (no in pts with
 primary arrhythmic disorders);
 second VT therapy 31 J; third-last
VT therapy 31/41 J
N/A
 VT-150 bpm; NID 16; ATP x 2; third
 VT therapy; maximum energy ( J not
specified) x 3
Figure 1: Flow Diagram of Eligible Studies
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Figure 2: Risk of Bias Summary for the Studies Included. Green 
Indicates Low Risk of Bias. Red Indicates High Risk of Bias. Yellow 
Indicates Unclear Risk of Bias
RAFT DFT = Resynchronization/Defibrillation for Am-
bulatory Heart Failure Trial; DFT = defibrillation test-
ing; NORDIC ICD = NO Regular Defibrillation Testing 
In Cardioverter Defibrillator Implantation (NORDIC 
ICD) Trial; SIMPLE = Shockless Implant Evaluation 
(SIMPLE) Trial; TNT ICD = TEST-NO TEST Im-
plantable Cardioverter Defibrillator Pilot Study; ICD = 
implantable-cardioverter defibrillator; CRT-D = cardiac 
resynchronization therapy with ICD; ESC = European 
Society of Cardiology; ACC = American College of Car-
diology; AHA = American Heart Association; HRS = 
Heart Rhythm Society; AF = atrial fibrillation; ARVC = 
arrhytmogrnic right ventricular cardiomyopathy; TEE = 
trans-esophgeal echocardiography; ICU = intensive care 
unit; BNP = B-type natriuretic peptide; CK = creatin ki-
nase; CK-MB = creatin kinase-MB; NYHA = New York 
heart Association; LVEF = left ventricular ejection frac-
tion; ACS = acute coronary syndrome; IV = intravenous; 
VT = ventricular tachycardia; VF = ventricular fibrilla-
tion; FVT = fast ventricular tachycardia; CNS = central 
nervous system; J = Joules; NID = number of intervals to 
detect; ATP = antitachycardia pacing therapy; bpm, beats 
per minute; s = seconds; N/A = not available.
Characteristics
The baseline characteristics of the patients are summarized 
in Table 2.
Table 2: Characteristics of the Patients in the Meta-Analysis
RAFT DFT NORDIC ICD SIMPLE TNT ICD
DFT (+) DFT (-) DFT (+) DFT (-) DFT (+) DFT (-) DFT (+) DFT (-)
Population, n 75 70 540 537 1253 1247 28 20
Age, years (SD) 65.9 (9.39) 67.9 (8.9) 64.9 (10.6) 64.7 (11.2) 63.0 (11.7) 62.6 (11.5) 64.0 (7.6) 63.1 (11.8)
Male sex, n (%) 60 (80) 54 (77) 443 (82.0) 430 (80.0) 1009 (80.5) 1015 (81.4) 20 (71.4) 12 (60.0)
Ischemic disease N/R N/R 360 (66.7) 341 (63.5) 799 (63.8) 821 (65.8) 16 (59.3) 11 (55.0)
Non-ischemic dilated cardiomyop-
athy
N/R N/R N/R N/R 414 (33.0) 392 (31.4) N/R N/R
Hypertrophic cardiomyopathy N/R N/R N/R N/R 53 (4.2) 42 (3.4) N/R N/R
 Long QT, Brugada syndrome, or
CPVT
N/R N/R N/R N/R 29 (2.3) 24 (1.9) N/R N/R
NYHA ≤ II, n (%) 75 (100) 70 (100) 266 (49.3) 257 (47.9) 410 (32.7) 404 (32.4) N/R N/R
NYHA ≥ III, n (%) 0 (0) 0 (0) 242 (44.8) 259 (48.2) 387 (30.9) 365 (29.3) N/R N/R




Atrial fibrillation n (%) 4 (5) 4 (6) 40 (7.4) 45 (8.4) 139 (11.1) 141 (11.3) N/R N/R
Successful ICD implant n (%) 72/75 (96)  70/70
(100)
534 (98.9) 533 (99.2) 1242 (99.1) 1236 (99.1) N/R N/R
Patients received DFT, n (%)^ 72 (96) 0 (0) 520 (97.4) 7 (1.3) 1218 (98.1) 9 (0.7) N/R N/R
 Intra-procedural system revision and
ICD re-programming n/total (%)
3/71 (4) 0/0 (0)  25/520
(4.8)
0/7 (0)  37/1119
(3.3)
N/R N/R N/R
Primary prevention, n (%) 71 (94.7) 66 (94.3) 439 (81.3) 434 (81.0) 924 (73.7) 889 (71.3) 23 (82.1) 20 (100.0)
Single-chamber ICD N/R N/R 230 (42.6) 236 (43.9) 552 (44.1) 569 (45.6) N/R N/R
Dual-chamber ICD N/R N/R 129 (23.9) 116 (21.6) 324 (25.9) 319 (25,6) N/R N/R
CRT-D, n (%) 37 (49.3) 39 (55.7) 175 (32.4) 181 (33.6) 366 (29.2) 348 (27.9) N/R N/R
Right-sided device implant N/R N/R 3 (0.5) 6 (1.1) 13 (1.0) 15 (1.2) N/R N/R
Single-coil ICD lead N/R N/R 254 (47.6) 262 (49.2) N/R N/R N/R N/R
Dual-coil ICD lead N/R N/R 280 (51.6) 271 (50.5) 717 (57.2) 733 (58.8) N/R N/R
Amiodarone use, n (%) 12 (16%) 7 (10) 55 (10.2) 61 (11.4) 190 (15.2) 182 (14.6) N/R N/R
Beta-blockers use, n (%) 66 (88) 63 (90) 507 (93.9) 500 (93.1) 1088 (86.8) 1100 (88.0) N/R N/R
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RAFT-DFT= Resynchronization/Defibrillation for Ambula-
tory Heart Failure Trial; NORDIC-ICD = NO Regular Defi-
brillation Testing In Cardioverter Defibrillator Implantation 
Trial; SIMPLE = Shockless Implant Evaluation Trial; DFT = 
defibrillation testing; ICD = implantable cardioverter-defibril-
lator; CRT-D = ICD with resynchronization therapy; NYHA = 
New York Heart Association; LVEF = left ventricular ejection 
fraction; CPVT = catecholaminergic polymorphic ventricular 
tachycardia; DFT (+) = defibrillation testing; DFT (-) = no-de-
fibrillation testing; N/R = not reported (One Patient in RAFT-
DFT and One Patient in NORDIC-ICD were not Inducible).
Primary Outcome
All-Cause Mortality
Data on mortality were analyzed in the intention-to-treat 
cohort. A total of 535 deaths (14.2%) were reported. No 
significant difference in the risk of death (RR = 1.00, 95% 
CI 0.86–1.17; P = 0.98) was observed with DFT versus no-
DFT (Fig 3). There was no significant heterogeneity among 
the 4 studies (I2 = 0%; P = 0.39). A sensitivity analysis re-
vealed that no individual study had a predominant impact. 
However, the overall estimated RR increased to 1.24 (95% 
CI 0.86–1.79; P = 0.24) when SIMPLE was excluded.
Secondary Outcomes
TNT ICD did not report the number of patients with ar-
rhythmic death, and the number of first or any appropriate 
shock efficacy; so, the study was removed from the analy-
ses.
Arrhythmic Death
Arrhythmic death occurred in 144 patients (3.9%) and 
was similar between groups (RR = 1.60, 95% CI 0.46-5.59: 
P = 0.46) (Fig 4). There was no significant heterogeneity 
among the included studies (I2 = 45%; P = 0.18). On sensi-
tivity analysis, while no individual study had a predominant 
impact, the overall estimated RR increased to 4.97 (95% CI 
0.58–42.42; P = 0.14) when SIMPLE was excluded.
Shock Efficacy
The analyses yielded the pooled effect-estimate in the 
on-treatment cohort. During follow-up, appropriate shock 
efficacy was reduced in the DFT group compared with the 
no-DFT group, with a statistically significant difference 
(RR = 0.97, 95% CI 0.95–1.00; P = 0.02) (Fig 5). When 
we considered the first appropriate ICD shock, the pooled 
effect-estimate indicated a somewhat lower efficacy in the 
no-DFT group (RR = 0.94, 95% CI 0.89–0.98; P = 0.004) 
(Fig 6). The sensitivity analysis suggested that NORDIC 
ICD had the greatest impact on statistical significance, and 
the overall estimated RR decreased to 0.96 (95% CI 0.90–
1.02; P = 0.17) when the study was omitted.
Figure 3: Meta-Analysis of All-Cause Mortality. The Risk Ratio for Mortality with DF (+) was not Statistically Significant from DF (-) 
Follow-Up. DF, Defibrillation Threshold. CI, Confidence Interval. M-H, Mantel–Haenszel.
Figure 4: Meta-Analysis of Arrhythmic Death. The Risk Ratio for Arrhythmic Death with DF (+) was not Statistically Significant from DF 
(-) Follow-Up. Abbreviations as in Figure 3.
Figure 5: Meta-Analysis of any Appropriate Shock Efficacy. DF (+) Demonstrated A Nonsignificant Trend toward Fewer Appropriate 
Shock Efficacy. Abbreviations as in Figure 3.
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Figure 6: Meta-Analysis of First Appropriate Shock Efficacy. DF (+) Demonstrated A Significant Fewer First Appropriate Shock Efficacy. 
Abbreviations as in Figure 3.
Figure 7: Meta-Analysis of Major Adverse Events. Pooled Data Showed A Significant Reduction in the Risk of Adverse Events with DF (-). 
Abbreviations as in Figure 3.
Safety Outcomes
A total of 327 patients had procedural adverse events and 
complications related to ICD implantation, 181 of whom 
had undergone DFT and 146 had not (RR = 1.23; 95% CI 
1.00–1.51; P = 0.05) (Fig 7). There was no statistical hetero-
geneity among the studies (I2 = 0%; P = 0.86). On sensitivi-
ty analysis, two studies had a major impact on the statistical 
analysis; the overall estimated RR decreased to 1.18 (95% CI 
0.87-1.60; P = 0.27) when NORDIC ICD was excluded, and 
increased to 1.28 (95% CI 0.97-1.68; P = 0.08) when SIM-
PLE was omitted. The 30-day procedure-related mortality 
rate was 0.3% in the DFT group and 0.5% in the no-DFT 
group (RR = 0.69, 95% CI 0.25 – 1.88; P = 0.46). The proce-
dure-related stroke rate was 0.2% in patients with DFT and 
0.4% in those without DFT (RR = 0.61, 95% CI 0.17 – 2.25; 
P = 0.46). Finally, intraoperative hypotension was the only 
adverse event somewhat more frequent in patients with DFT 
(1.1% vs. 0.3%; RR = 3.83, 95% CI 0.69 – 21.31; P = 0.13).
DISCUSSION
Findings
The findings from our systematic review and meta-analysis 
suggest that DFT at the time of ICD implantation has no 
impact on all-cause mortality or arrhythmic death during 
follow-up. Unexpectedly, the effect estimate reveals a 2% to 
11% statistically significant lower first appropriate shock effi-
cacy in the group with DFT versus those with no-DFT. This 
outcome was greatly influenced by the results of NORDIC 
ICD, which used higher programmed first shock energy (40 
J) than SIMPLE (31J) and RAFT DFT (25J). Furthermore, 
a reduction was found in any appropriate shock efficacy in 
interrupting ventricular arrhythmias in the DFT group. This 
result was not affected by any single study, as the shocks 
delivered after the first were programmed to the maximum 
energy (from 31 J to 41 J) and did not differ greatly in num-
ber in the included studies. RAFT DFT, SIMPLE, NORDIC 
ICD, and TNT ICD demonstrated similar modest increases 
in overall procedural safety outcomes, which did not quite 
reach statistical significance in any individual trial. When we 
pooled the data, DFT was associated with a statistically sig-
nificant 23% increased risk of total procedural adverse events 
and complications. This result was mainly driven by a single 
adverse event (intraoperative hypotension).
Strengths of our Analysis
To the best of our knowledge, this is the first systematic re-
view and meta-analysis of RCTs to compare the efficacy and 
safety of DFT at time of ICD implantation. Our results are 
consistent with previous observational data [12-22] and me-
ta-analyses [5, 23] and provide further support to the recom-
mendation to omit defibrillation efficacy testing in patients 
undergoing initial transvenous ICD implantation procedures 
[24]. Nonetheless, these results do not apply to specific sub-
groups, which were excluded or poorly represented in this 
meta-analysis, such as patients with right-sided ICD pocket 
or non-transvenous systems; patients with congenital heart 
diseases, channelopathies or hypertrophic cardiomyopathy; 
and patients who undergo device replacement. Ventricular 
fibrillation is induced during ICD implantation to assess: 
(1) electrical integrity of the connections between the leads 
and pulse generator; (2) reliable sensing, detection, and re-
detection in VF; and (3) optimal, or at least adequate, pro-
grammed shock strength. Low voltage pulses or shocks in 
normal rhythm can achieve the first goal. Concerning the 
second point, several studies have demonstrated a strong 
correlation between R wave amplitude in native rhythm and 
reliable sensing during induced and spontaneous VF. If the 
R wave during native rhythm is ≥5–7 mV, sensing during VF 
is almost always sufficient to ensure rapid detection or rede-
tection [25, 26]. Based on these considerations, the issue of 
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whether to perform DFT is confined to the third point. As-
sessing the value of DFT requires considering four questions: 
(1) Does it predict shock success for induced VF? (2) Does 
it predict shock success for spontaneous VT/VF? (3) What 
is the relationship between DFT and conversion of sponta-
neous ventricular tachyarrhythmias? (4) Does it predict total 
mortality or sudden death? The studies included in our me-
ta-analysis used a 10 J “safety-margin” criterion on implan-
tation. This method limits testing to the minimum number 
of induced episodes necessary to determine whether there is 
a sufficient safety-margin (i.e. 10 J) between the maximum 
shock strength of the ICD and the shock strength required for 
consistent defibrillation. Data from the studies indicate that 
an extremely high number of patients (97.1%) were success-
fully defibrillated at the tested shock strength. While device 
revision provided no benefit during follow-up, patients in the 
DFT group underwent unnecessary system revision and/or 
ICD reprogramming [27]. The primary assumption of intra-
operative DFT is that successful defibrillation on implanta-
tion will predict successful treatment of clinical ventricular 
arrhythmias. Our results indicate that the efficacy of the first-
shock in interrupting spontaneous rapid VT or VF ranged 
from 87.0% in the DFT patients to 93.2% in the no-DFT 
group. This observation suggests that shocks for spontaneous 
VT/VF may not be effective for reasons that are not evalu-
ated on implantation, therefore negating the utility of DFT. 
Furthermore, the first-shock success rate in spontaneous 
VT/VF has a weak relationship with the total conversion rate 
for VT/VF. Implantable cardioverter-defibrillators deliver 
up to six or eight shocks for VT/VF at maximum strength, 
so that subsequent shocks may succeed if the first fails, and 
better implant testing did not reduce overall shock efficacy. 
Finally, DFT had a neutral effect on mortality. Data regarding 
the relationship between ICD implant testing and either to-
tal mortality or arrhythmic death are limited and difficult to 
interpret for several reasons. Factors that cannot be tested on 
implantation probably cause some failed shocks or sudden 
death. Such factors include ischemia, progressive heart fail-
ure, metabolic abnormalities, drug effects, and ICD lead or 
generator failures. Further, it is difficult to establish how often 
a high DFT is caused by an inadequate ICD system, and how 
often it is an indirect marker of a “sicker” patient. It is reason-
able to accept that patients with unreliable defibrillation on 
implantation have a clinically higher risk of sudden death. Fi-
nally, some sudden cardiac deaths in ICD patients are caused 
by malfunctions of ICD leads or pulse generators, which 
are undetectable at time of implantation [28, 29]. Another 
important question for this review concerns the risks of de-
fibrillation on implantation. The risks of DFT include those 
related to induction of VF and those related to shocks alone. 
The anesthesia required for the delivery of shocks is another 
potential cause of complications. Data from our meta-analy-
sis indicate that adverse events and complications following 
ICD implantation are uncommon, and rarely lead to death or 
permanent disability. Therefore, specific complications that 
occurred more frequently in patients with DFT were typical-
ly short-lived, such as intraoperative hypotension.
Limitations
 The results of our meta-analysis are weakened by limitations 
inherent in meta-analyses and in the included studies. The 
low number of studies included meant that statistical power 
was low, especially for safety data analysis. The analysis of rare 
events carries its own limitations, in that even a small change 
in the number of events can produce a dramatic change in 
the results. Our pooled effect estimate included trials that dif-
fered in terms of follow-up. NORDIC ICD had a shorter fol-
low-up than SIMPLE (22.8 versus 37 months) and, although 
the patient populations in the two studies were comparable, 
the overall mortality rate was lower in NORDIC ICD, which 
is indicative of a “less sick” patient cohort. RAFT DFT had 
a follow-up comparable with that of NORDID ICD, but 
included only patients in NYHA II functional class. It is 
noteworthy that NORDIC ICD collected data not only on 
protocol-specified complications but also on all procedure- 
and patient-related adverse events, which may have affected 
the results of our safety analysis. Finally, there was a lack of 
detailed information on intra-operative complications in 
NORDIC ICD and TNT ICD. SIMPLE and NORDIC ICD 
reported losses to follow-up that were greater in each trial’s 
no-DFT group, though the overall difference of being lost to 
follow-up was not statistically significant (RR = 1.62; 95% CI 
0.90 – 2.93; P = 0.11).
This meta-analysis demonstrated that routine DFT at the 
time of ICD implantation was substantially safe, but did not 
improve shock efficacy or reduce mortality in comparison 
with the no-testing strategy. It is therefore expected that the 
results of the meta-analysis will lead to abandonment of the 
practice of VF testing in selected patients who underwent 
transvenous ICD implantation.
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